Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03549260 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction
A Phase 2 study of LDL Cholesterol, sponsored by LIB Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 5
- Study locations
NCT03549260: Completed Phase 2 study of LDL Cholesterol, sponsored by LIB Therapeutics.
NCT03549260 is a Phase 2 study of LDL Cholesterol that has completed, run by LIB Therapeutics. The registered enrollment target is 81 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03549260, a Phase 2 study of LDL Cholesterol, has completed, sponsored by LIB Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 5
- Study locations
Study Summary
Study to assess the LDL-C lowering efficacy of different doses of LIB003 administered every 4 weeks in subjects on stable statin and/or ezetimibe therapy
Conditions Studied
Interventions
- BIOLOGICAL LIB003
Study Locations (5)
Ohio
- Sterling Research Group - Cincinnati
- The Lindner Research Center - Cincinnati
- Metabolic & Atherosclerosis Research Center (MARC) - Cincinnati
Indiana
- Midwest Institute For Clinical Research - Indianapolis
Kentucky
- Louisville Metabolic and Atherosclerosis Research Center - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2018-05-22 |
| Est. Completion | 2018-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03549260
The ClinicalTrials.gov registry entry for NCT03549260 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% lower). The listed sponsor is LIB Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with LDL Cholesterol appearing as the primary indexed condition, and to 1 intervention - of which LIB003 is the first listed.
NCT03549260 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Ohio, Indiana, Kentucky.
Frequently Asked Questions
What is clinical trial NCT03549260 about?
NCT03549260 is a clinical study titled "Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction". Study to assess the LDL-C lowering efficacy of different doses of LIB003 administered every 4 weeks in subjects on stable statin and/or ezetimibe therapy
What is the current status of trial NCT03549260?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2018-05-22. Estimated completion is 2018-11-30.
What conditions does trial NCT03549260 study?
This clinical trial studies the following conditions: LDL Cholesterol.
What interventions are being tested in trial NCT03549260?
The interventions under investigation include: LIB003 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03549260?
This trial is sponsored by LIB Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03549260 being conducted?
This trial has 5 study locations across Indiana, Kentucky, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00093964 · 81 participants · Phase 2
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
- NCT00198107 · 81 participants · Phase 3
Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism
- NCT00243906 · 81 participants · Phase 2
Interventional Management of Stroke (IMS) II Study
- NCT00353886 · 81 participants
Study of Antiepileptic Drug Effects on Child Development
Similar registry start date
- NCT05684068 · started 2028-08 · NA
Dimensional Changes: Randomized Clinical Trial
- NCT07167953 · started 2028-08 · NA
The Spiral MRI Study
- NCT07215013 · started 2028-07 · NA
Acoustic Resonance Therapy for Treating Empty Nose Syndrome
- NCT07443332 · started 2028-07 · NA
Culturally Adapted Contingency Management
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.